Enveric Biosciences
ENVB
9 hedge funds and large institutions have $357K invested in Enveric Biosciences in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
0.01% less ownership
Funds ownership: 0.05% → 0.05% (-0.01%)
43% less capital invested
Capital invested by funds: $623K → $357K (-$266K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$117K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.64K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$553 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$46K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$8.85K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$2.77K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
1
AdvisorShares Investments
Bethesda,
Maryland
| $238K | +$117K | +211 | +49% |
|
2
BlackRock
New York
| $61.5K | – | – | – |
|
3
Vanguard Group
Malvern,
Pennsylvania
| $30K | – | – | – |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $21K | +$6.64K | +12 | +28% |
|
|
5
UBS Group
Zurich,
Switzerland
| $5K | -$8.85K | -16 | -55% |
|
|
6
Group One Trading
Chicago,
Illinois
| $560 | -$2.77K | -5 | -71% |
|
7
Bank of America
Charlotte,
North Carolina
| $208 | – | – | – |
|
8
Wells Fargo
San Francisco,
California
| $60 | – | – | – |
|
|
CS
9
Credit Suisse
Zurich,
Switzerland
| $2 | – | – | – |
|
10
Morgan Stanley
New York
| $2 | – | – | – |
|
|
11
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$46K | -61 | Closed |
|
|
12
Osaic Holdings
Scottsdale,
Arizona
| – | +$553 | +1 | New |
|
ENVB Hedge Fund Activity: Q4 2022 in Review
9 of the 6,223 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q4 2022, worth a combined $357K — down 43% from $623K a quarter earlier.
Fund positioning in ENVB was balanced in Q4 2022: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was AdvisorShares Investments, adding an estimated $117K. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $46K sold.
- 9 institutional investors held Enveric Biosciences (ENVB) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $357K of Enveric Biosciences stock for Q4 2022, down 43% quarter-over-quarter.
- 1 fund opened new Enveric Biosciences positions in Q4 2022 and 1 closed out, a net change of 0 holders.
- The largest Enveric Biosciences buyer in Q4 2022 was AdvisorShares Investments, an estimated $117K added.
- The largest Enveric Biosciences seller in Q4 2022 was Hudson Bay Capital Management, an estimated $46K sold.
Based on aggregated 13F filings for Q4 2022.